Kleiner Perkins Caufield & Byers XV, LLC 3
3 · RAPT Therapeutics, Inc. · Filed Oct 30, 2019
Insider Transaction Report
Form 3
Holdings
- (indirect: By KPCB Holdings, Inc., as nominee)
Series C Preferred Stock
→ Common Stock (363,504 underlying) - (indirect: By KPCB Holdings, Inc., as nominee)
Series A Preferred Stock
→ Common Stock (2,871,492 underlying) - (indirect: By KPCB Holdings, Inc., as nominee)
Series B Preferred Stock
→ Common Stock (166,666 underlying) - (indirect: By KPCB Holdings, Inc., as nominee)
Series C-2 Preferred Stock
→ Common Stock (145,401 underlying)
Footnotes (3)
- [F1]Each share of Series A, Series B, Series C and Series C-2 Preferred Stock is convertible into approximately 0.166 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019). Shares of Series A, Series B, Series C and Series C-2 Preferred Stock have no expiration date and will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock, for no additional consideration.
- [F2]The number of shares of common stock reflects a 1-for-6 reverse stock split, which became effective July 19, 2019.
- [F3]The shares held for convenience in the name of KPCB Holdings, Inc., as nominee for the accounts of the following entities as follows: 3,444,199 shares held for the account of Kleiner Perkins Caufield & Byers XV, LLC ("KPCB XV") and 102,864 shares held for the account of KPCB XV Founders Fund, LLC ("KPCB XV FF"). The managing member of KPCB XV and KPCB XV FF is KPCB XV Associates, LLC ("KPCB XV Associates"). Beth Seidenberg, L. John Doerr, Randy Komisar, Theodore E. Schlein, Wen Hsieh and William "Bing" Gordon, the managing members of KPCB XV Associates, exercise shared voting and dispositive control over the shares held by KPCB Holdings, Inc. as nominee for the accounts of KPCB XV and KPCB XV FF.